NZ628479A - Methods and compositions for administration of oxybutynin - Google Patents
Methods and compositions for administration of oxybutyninInfo
- Publication number
- NZ628479A NZ628479A NZ628479A NZ62847913A NZ628479A NZ 628479 A NZ628479 A NZ 628479A NZ 628479 A NZ628479 A NZ 628479A NZ 62847913 A NZ62847913 A NZ 62847913A NZ 628479 A NZ628479 A NZ 628479A
- Authority
- NZ
- New Zealand
- Prior art keywords
- salt
- oxybutynin
- agents
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient’s lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/728,706 US9119777B2 (en) | 2008-05-30 | 2012-12-27 | Methods and compositions for administration of oxybutynin |
| PCT/US2013/074759 WO2014105446A1 (en) | 2012-12-27 | 2013-12-12 | Methods and compositions for administration of oxybutynin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628479A true NZ628479A (en) | 2016-06-24 |
Family
ID=51021931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628479A NZ628479A (en) | 2012-12-27 | 2013-12-12 | Methods and compositions for administration of oxybutynin |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2938329A4 (en) |
| JP (1) | JP2016504358A (en) |
| KR (1) | KR20150100902A (en) |
| CN (1) | CN104955444A (en) |
| AR (1) | AR094287A1 (en) |
| AU (1) | AU2013368298B2 (en) |
| BR (1) | BR112015015421A2 (en) |
| CA (1) | CA2895955A1 (en) |
| EA (1) | EA201591218A1 (en) |
| HK (2) | HK1215396A1 (en) |
| IL (1) | IL239623A0 (en) |
| MX (1) | MX2015008333A (en) |
| NZ (1) | NZ628479A (en) |
| UY (1) | UY35230A (en) |
| WO (1) | WO2014105446A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190046493A1 (en) * | 2016-02-25 | 2019-02-14 | Hisamitsu Pharmaceutical Co., Inc. | Liquid external preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2371923A1 (en) * | 1999-05-20 | 2000-11-30 | Thomas P. Jerussi | Methods for treatment of asthma using s-oxybutynin |
| US6339107B1 (en) * | 2000-08-02 | 2002-01-15 | Syntex (U.S.A.) Llc | Methods for treatment of Emphysema using 13-cis retinoic acid |
| BR0315258A (en) * | 2002-10-29 | 2005-08-23 | Pharmacia & Upjohn Co Llc | Quaternary ammonium compounds |
| GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| WO2006047427A1 (en) * | 2004-10-25 | 2006-05-04 | Schering Corporation | M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders |
| US8415390B2 (en) * | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| EP3311820A1 (en) * | 2008-02-26 | 2018-04-25 | Sunovion Respiratory Development Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2442657A4 (en) * | 2009-06-16 | 2012-11-07 | Wen Tan | Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders |
| GB0918450D0 (en) * | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
| RU2585101C2 (en) * | 2010-04-01 | 2016-05-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Method for producing carrier particles for dry powders for inhalations |
| JP2013538830A (en) * | 2010-09-27 | 2013-10-17 | マイクロドース セラピューテクス，インコーポレイテッド | Methods and compositions for treatment of diseases using inhalation |
-
2013
- 2013-12-12 WO PCT/US2013/074759 patent/WO2014105446A1/en active Application Filing
- 2013-12-12 CN CN201380068230.5A patent/CN104955444A/en active Pending
- 2013-12-12 EA EA201591218A patent/EA201591218A1/en unknown
- 2013-12-12 MX MX2015008333A patent/MX2015008333A/en unknown
- 2013-12-12 EP EP13867956.8A patent/EP2938329A4/en not_active Withdrawn
- 2013-12-12 AU AU2013368298A patent/AU2013368298B2/en not_active Ceased
- 2013-12-12 BR BR112015015421A patent/BR112015015421A2/en not_active IP Right Cessation
- 2013-12-12 NZ NZ628479A patent/NZ628479A/en not_active IP Right Cessation
- 2013-12-12 KR KR1020157020335A patent/KR20150100902A/en not_active Application Discontinuation
- 2013-12-12 CA CA2895955A patent/CA2895955A1/en not_active Abandoned
- 2013-12-12 JP JP2015550444A patent/JP2016504358A/en active Pending
- 2013-12-20 UY UY0001035230A patent/UY35230A/en not_active Application Discontinuation
- 2013-12-27 AR ARP130105037A patent/AR094287A1/en unknown
-
2015
- 2015-06-24 IL IL239623A patent/IL239623A0/en unknown
-
2016
- 2016-03-23 HK HK16103431.3A patent/HK1215396A1/en unknown
- 2016-04-25 HK HK16104715.8A patent/HK1216843A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2938329A1 (en) | 2015-11-04 |
| EA201591218A1 (en) | 2015-11-30 |
| EP2938329A4 (en) | 2016-08-10 |
| WO2014105446A1 (en) | 2014-07-03 |
| CA2895955A1 (en) | 2014-07-03 |
| KR20150100902A (en) | 2015-09-02 |
| HK1215396A1 (en) | 2016-08-26 |
| AR094287A1 (en) | 2015-07-22 |
| MX2015008333A (en) | 2015-11-09 |
| BR112015015421A2 (en) | 2017-07-11 |
| JP2016504358A (en) | 2016-02-12 |
| HK1216843A1 (en) | 2016-12-09 |
| CN104955444A (en) | 2015-09-30 |
| AU2013368298A1 (en) | 2015-07-02 |
| AU2013368298B2 (en) | 2016-08-11 |
| UY35230A (en) | 2015-01-30 |
| IL239623A0 (en) | 2015-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120049T1 (en) | (2S) -N - [(1S) -1-Cyano-2-phenylethyl] -1,4-oxazepan-2-carboxamide as inhibitors of dipeptidyl peptide I | |
| PH12015501108B1 (en) | Treatment of pulmonary disease | |
| UA115139C2 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
| MX355742B (en) | 4-hydroxybutyric acid deuterated analogs. | |
| PH12015501404B1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| MX369385B (en) | Products for healing of tissue wounds. | |
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| MX2019002774A (en) | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease. | |
| IN2014MN01755A (en) | ||
| EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
| NZ726366A (en) | Syk inhibitors | |
| WO2014067986A8 (en) | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis | |
| MX366393B (en) | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propy l)-phenol. | |
| WO2012071369A3 (en) | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease | |
| MX2015008187A (en) | Deuterated alk inhibitors. | |
| BR112014010729A2 (en) | methods for treating gout attacks | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
| TR201900438T4 (en) | Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome. | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| BR112014004737A2 (en) | Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound | |
| NZ628479A (en) | Methods and compositions for administration of oxybutynin | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |